Reference health
COVID-19 Among Patients With Inflammatory Rheumatic Diseases
25/25 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 25 checked references that resolve
resolves10.1001/jama.2020.2648
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
resolves10.1007/s00038-020-01390-7
Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis
resolves10.1007/s00296-020-04629-x
Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes
resolves10.1016/S2665-9913(20)30227-7
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
resolves10.55563/clinexprheumatol/xcdary
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
resolves10.1136/annrheumdis-2020-217871
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
resolves10.1016/j.jbi.2008.08.010
Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
resolves10.1016/S2665-9913(20)30169-7
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study
resolves10.1007/s00296-020-04676-4
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes
resolves10.1136/annrheumdis-2020-218296
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
resolves10.1136/annrheumdis-2020-217984
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
resolves10.1053/j.gastro.2020.05.032
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
resolves10.1136/annrheumdis-2020-219498
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
resolves10.1016/j.jbspin.2020.05.003
Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy
resolves10.1002/art.41388
Incidence of COVID‐19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
resolves10.1136/annrheumdis-2020-217903
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study
resolves10.1016/j.semarthrit.2020.05.001
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
resolves10.1007/s10067-020-05334-7
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
resolves10.1056/NEJMoa2012410
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
resolves10.1001/jama.2020.8630
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
resolves10.1136/bmj.m1849
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
resolves10.1056/NEJMoa2019014
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
The 1 reference without a DOI — listed, not checked
no DOI — not checkedWHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis2020
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3389/fimmu.2021.651715"><img src="https://citestamp.com/citestamped/10.3389/fimmu.2021.651715/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3389/fimmu.2021.651715)